Inhibikase Therapeutics, Inc. issued a Letter to Shareholders. What a ride it has been in 2023. The year began with a quick recovery in January from a brief clinical hold for risvodetinib as well as the successful closing of a $10 million equity raise to support the advancement of neurodegenerative and cancer therapeutics programs. Based on the current pace of enrollment, the expect to report results from this trial in the second half of 2024.

approach with Multiple System Atrophy, an aggressive form of Parkinson's disease, has seen similar success in 2023. The company opened an IND for direct entry into a Phase 2 clinical trial and have received Orphan Drug Designation for risvodetinIB as a treatment for MSA from the FDA, although the trial start date is yet to be determined. The company plan to submit complementary regulatory documents for risvodet in non-oncology indications to which imatinib has already been shown to have meaningful benefit.

The company look forward to providing updates on this progress in the first half of 2024. Across the therapeutic pipeline, the company have developed technologies that will advance clinical development and may augment commercial success. For risvodetinib, a commercial tablet formulation was developed that doubles drug exposure at the same dose.

The company believe this formulation significantly improves oral drug absorption. As always, transparency remains a core principle.